BeiGene | A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Beigene Study ID

BGB-290-104

ClinicalTrials.gov ID

NCT03150862

EudraCT Number

2017-001554-33

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan